- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million | 114 | GlobeNewswire (Europe) | Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first... ► Artikel lesen | |
| 25.08. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| KORSANA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 10.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 09.06. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock Cyclerion Therapeutics Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion Therapeutics reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 952 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 322 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 211 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen | |
| 23.09.25 | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Transformational Relaunch as a Neuropsychiatric Company | 350 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,120 | +0,43 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| EDITAS MEDICINE | 2,410 | -7,66 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,978 | +3,34 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| CARDIFF ONCOLOGY | 0,906 | -4,68 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,250 | -5,52 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| EMERGENT BIOSOLUTIONS | 4,898 | -5,08 % | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG... ► Artikel lesen | |
| DENALI THERAPEUTICS | 18,330 | -3,48 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,570 | -4,70 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,157 | -2,20 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,044 | -3,21 % | CytomX auf Wells-Fargo-Konferenz: Fokus auf EpCAM-Wirkstoff und solide Liquidität | ||
| FATE THERAPEUTICS | 2,166 | +0,84 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting | SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent... ► Artikel lesen | |
| FAETH THERAPEUTICS | 31,400 | -9,25 % | TD Cowen initiates Faeth Therapeutics stock with buy rating | ||
| CYBIN | 11,620 | +9,42 % | CYBIN INC. - 6-K, Report of foreign issuer | ||
| ESPERION | 2,709 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 13.07.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.07.2026ISIN NameCA05337L3048 AVALON... ► Artikel lesen | |
| CAPRICOR | 7,670 | -1,67 % | Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026 |
Das Unternehmen KORSANA BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +19,060 (+567,26 %) liegt der Kurs bei 22,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KORSANA BIOSCIENCES INC finden Sie auf Wallstreet Online.